Drug Profile
CPL 2009-0031
Alternative Names: CPL-2009-0031Latest Information Update: 25 Jul 2022
Price :
$50
*
At a glance
- Originator Cadila Pharmaceuticals
- Class Amides; Antihyperglycaemics; Antihypoglycaemics; Fluorobenzenes; Piperazines; Triazoles
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Type 2 diabetes mellitus
Most Recent Events
- 25 Jul 2022 CPL 2009-0031 is still in phase III trials for Type-2 diabetes mellitus (Treatment-experienced) in India (PO, Tablet) (Cadila Pharmaceuticals pipeline, July 2022)
- 11 Feb 2021 Cadila Pharmaceuticals completes a phase III trial in Type-2 diabetes mellitus (Treatment-experienced) in India (PO, Tablet) (CTRI2019-04-018763) (NCT04801199)
- 26 Sep 2019 Cadila Pharmaceuticals plans a phase III trial for Type-2 diabetes mellitus (Treatment-experienced) in India (PO, Tablet) (CTRI2019-04-018763)